Nanotechnology-based gene therapy as a credible tool in the treatment of Alzheimer’s disease
暂无分享,去创建一个
[1] Pei-pei Jia,et al. Treatment of Alzheimer's disease with small-molecule photosensitizers , 2022, Chinese Chemical Letters.
[2] V. Sytnyk,et al. Amyloid precursor protein (APP) and amyloid β (Aβ) interact with cell adhesion molecules: Implications in Alzheimer’s disease and normal physiology , 2022, Frontiers in Cell and Developmental Biology.
[3] A. Mahfuz,et al. Designing potential siRNA molecules for silencing the gene of the nucleocapsid protein of Nipah virus: A computational investigation. , 2022, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[4] Weihong Song,et al. The synapse as a treatment avenue for Alzheimer’s Disease , 2022, Molecular Psychiatry.
[5] Zihua Wang,et al. Recent Advances in the Application of Mesenchymal Stem Cell-Derived Exosomes for Cardiovascular and Neurodegenerative Disease Therapies , 2022, Pharmaceutics.
[6] Y. Zhang,et al. Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential , 2022, Translational neurodegeneration.
[7] J. Mclarnon,et al. A Leaky Blood–Brain Barrier to Fibrinogen Contributes to Oxidative Damage in Alzheimer’s Disease , 2021, Antioxidants.
[8] S. Ganesh,et al. siRNA Mediated GSK3β Knockdown Targets Insulin Signaling Pathway and Rescues Alzheimer's Disease Pathology: Evidence from In Vitro and In Vivo Studies. , 2021, ACS applied materials & interfaces.
[9] J. Lübke,et al. Neurotrophic factors in Alzheimer's disease: pathogenesis and therapy. , 2021, Acta neurobiologiae experimentalis.
[10] A. Cuello,et al. The Nerve Growth Factor Metabolic Pathway Dysregulation as Cause of Alzheimer’s Cholinergic Atrophy , 2021, Cells.
[11] F. Javaherforooshzadeh,et al. Therapeutic potential of neurotrophic factors in Alzheimer’s Disease , 2021, Molecular Biology Reports.
[12] Andrew J Want,et al. Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm , 2021, EBioMedicine.
[13] L. Schneider,et al. Alzheimer’s drugs: Does reducing amyloid work? , 2021, Science.
[14] E. Kucharska,et al. Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings , 2021, Cells.
[15] F. Chen,et al. Neuroprotective Potential of Mung Bean (Vigna radiata L.) Polyphenols in Alzheimer's Disease: A Review. , 2021, Journal of agricultural and food chemistry.
[16] D. Selkoe. Treatments for Alzheimer's disease emerge , 2021, Science.
[17] A. Mahmoudi,et al. Synthesis of Nanocomposites Based on Mesoporous Aluminosilicate and Polyethyleneimine (PEI) for siRNA Delivery: Potential Usefulness of the Synergistic Effect of Al3+ ion and PEI on the siRNA Delivery Efficiency for Diseases Treatment , 2021 .
[18] W. Banks,et al. Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier , 2021, Advanced science.
[19] F. Tay,et al. Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy , 2021, Advanced science.
[20] V. Rani,et al. Modulating host gene expression via gut microbiome–microRNA interplay to treat human diseases , 2021, Critical reviews in microbiology.
[21] S. Mishra,et al. A review on ferulic acid and analogs based scaffolds for the management of Alzheimer's disease. , 2021, European journal of medicinal chemistry.
[22] Rita N. Wadetwar,et al. Nanocarriers: A Tool for Effective Gene Delivery , 2021 .
[23] Liang Han,et al. Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies , 2020, Acta pharmaceutica Sinica. B.
[24] A. Bush,et al. Blood-brain barrier–penetrating siRNA nanomedicine for Alzheimer’s disease therapy , 2020, Science Advances.
[25] B. Palaniappan,et al. Role of tau protein in Alzheimer's disease: The prime pathological player. , 2020, International journal of biological macromolecules.
[26] Haifa Shen,et al. Nanoplatforms for mRNA Therapeutics , 2020 .
[27] Fan Yang,et al. Brain‐targeted co‐delivery of β‐amyloid converting enzyme 1 shRNA and epigallocatechin‐3‐gallate by multifunctional nanocarriers for Alzheimer's disease treatment , 2020, IUBMB life.
[28] M. Stepanichev. Gene Editing and Alzheimer's Disease: Is There Light at the End of the Tunnel? , 2020, Frontiers in Genome Editing.
[29] Jagdish Singh,et al. Nerve Growth Factor gene delivery across the blood brain barrier to reduce beta amyloid accumulation in AD mice. , 2020, Molecular pharmaceutics.
[30] Beob Soo Kim,et al. Systemic Brain Delivery of Antisense Oligonucleotides across the Blood–Brain Barrier with a Glucose‐Coated Polymeric Nanocarrier , 2020, Angewandte Chemie.
[31] Juan C. Cruz,et al. Multifunctional magnetite nanoparticles to enable delivery of siRNA for the potential treatment of Alzheimer’s , 2020, Drug delivery.
[32] A. Groisman,et al. Neuroprotective Effect of Nerve Growth Factor Loaded in Porous Silicon Nanostructures in an Alzheimer's Disease Model and Potential Delivery to the Brain. , 2019, Small.
[33] A. Aigner. Perspectives, issues and solutions in RNAi therapy: the expected and the less expected. , 2019, Nanomedicine.
[34] Jagdish Singh,et al. ApoE-2 Brain-Targeted Gene Therapy Through Transferrin and Penetratin Tagged Liposomal Nanoparticles , 2019, Pharmaceutical Research.
[35] H. Zoghbi,et al. Loss of Ataxin-1 Potentiates Alzheimer’s Pathogenesis by Elevating Cerebral BACE1 Transcription , 2019, Cell.
[36] B. de Strooper,et al. AAV mediated delivery of a novel anti-BACE1 VHH reduces Abeta in an Alzheimer’s disease mouse model , 2019, bioRxiv.
[37] M. Mahmoudi,et al. Impact of Gold Nanoparticles on Amyloid β-Induced Alzheimer's Disease in a Rat Animal Model: Involvement of STIM Proteins. , 2019, ACS chemical neuroscience.
[38] Divya Rai,et al. Nanomaterials-Based siRNA Delivery: Routes of Administration, Hurdles and Role of Nanocarriers , 2019, Nanotechnology in Modern Animal Biotechnology.
[39] Scott G. Mitchell,et al. Current status and future perspectives of gold nanoparticle vectors for siRNA delivery. , 2019, Journal of materials chemistry. B.
[40] C. Lengner,et al. In vivo neuronal gene editing via CRISPR–Cas9 amphiphilic nanocomplexes alleviates deficits in mouse models of Alzheimer’s disease , 2019, Nature Neuroscience.
[41] A. Borreca,et al. NGF-Dependent Changes in Ubiquitin Homeostasis Trigger Early Cholinergic Degeneration in Cellular and Animal AD-Model , 2018, Front. Cell. Neurosci..
[42] Guy C. Brown,et al. Effective Knockdown of Gene Expression in Primary Microglia With siRNA and Magnetic Nanoparticles Without Cell Death or Inflammation , 2018, Front. Cell. Neurosci..
[43] Peng Yang,et al. Systemic delivery of BACE1 siRNA through neuron‐targeted nanocomplexes for treatment of Alzheimer's disease , 2018, Journal of controlled release : official journal of the Controlled Release Society.
[44] Z. Cai,et al. Role of Blood-Brain Barrier in Alzheimer's Disease. , 2018, Journal of Alzheimer's disease : JAD.
[45] O. Farokhzad,et al. Nanotechnology-Based Strategies for siRNA Brain Delivery for Disease Therapy. , 2018, Trends in biotechnology.
[46] Chi Zhang,et al. A Dual Targeting Drug Delivery System for Penetrating Blood-Brain Barrier and Selectively Delivering siRNA to Neurons for Alzheimer's Disease Treatment. , 2018, Current pharmaceutical biotechnology.
[47] G. Petsko,et al. AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. , 2018, Human gene therapy. Clinical development.
[48] P. Haydon,et al. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice , 2018, Molecular Neurodegeneration.
[49] J. Chakraborty,et al. siRNA-nanoparticle conjugate in gene silencing: A future cure to deadly diseases? , 2017, Materials science & engineering. C, Materials for biological applications.
[50] Su Jeong Song,et al. Polyamidoamine (PAMAM) Dendrimers Modified with Cathepsin-B Cleavable Oligopeptides for Enhanced Gene Delivery , 2017, Polymers.
[51] B. Sarmento,et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer's therapy. , 2017, Colloids and surfaces. B, Biointerfaces.
[52] N. Robertson,et al. Treatments in Alzheimer’s disease , 2017, Journal of Neurology.
[53] Sandro Alves,et al. Gene Therapy Strategies for Alzheimer's Disease: An Overview. , 2016, Human gene therapy.
[54] H. Malkki. Alzheimer disease: NGF gene therapy activates neurons in the AD patient brain , 2015, Nature Reviews Neurology.
[55] Edward A. White,et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targeted siRNA delivery. , 2014, Biomaterials.
[56] Y. Kuo,et al. Protection of SK-N-MC cells against β-amyloid peptide-induced degeneration using neuron growth factor-loaded liposomes with surface lactoferrin. , 2014, Biomaterials.
[57] S. Lesieur,et al. Multicompartment Lipid Nanocarriers for Targeting of Cells Expressing Brain Receptors , 2012 .
[58] Jeong Yu Lee,et al. Prolonged gene silencing by siRNA/chitosan-g-deoxycholic acid polyplexes loaded within biodegradable polymer nanoparticles. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[59] Justin Tan,et al. Nanoporous Peptide Particles for Encapsulating and Releasing Neurotrophic Factors in an Animal Model of Neurodegeneration , 2012, Advanced materials.
[60] Shengliang Li,et al. Delivery of Quantum Dot-siRNA Nanoplexes in SK-N-SH Cells for BACE1 Gene Silencing and Intracellular Imaging , 2012, Molecular therapy. Nucleic acids.
[61] S. Lesieur,et al. SAXS Study of Sterically Stabilized Lipid Nanocarriers Functionalized by DNA , 2012 .
[62] Jianxu Li,et al. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-β₂₅₋₃₅-treated rats following intranasal administration. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[63] W. Pardridge,et al. The Trojan Horse Liposome Technology for Nonviral Gene Transfer across the Blood-Brain Barrier , 2011, Journal of drug delivery.
[64] S. Lesieur,et al. Topology and internal structure of PEGylated lipid nanocarriers for neuronal transfection : synchrotron radiation SAXS and cryo-TEM studies , 2011 .
[65] Boris Klebanov,et al. Influence of Cationic Lipid Composition on Gene Silencing Properties of Lipid Nanoparticle Formulations of siRNA in Antigen-Presenting Cells , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.
[66] C. Nyakas,et al. The basal forebrain cholinergic system in aging and dementia. Rescuing cholinergic neurons from neurotoxic amyloid-β42 with memantine , 2011, Behavioural Brain Research.
[67] M. Masserini,et al. The binding affinity of anti-Aβ1-42 MAb-decorated nanoliposomes to Aβ1-42 peptides in vitro and to amyloid deposits in post-mortem tissue. , 2011, Biomaterials.
[68] W. Pardridge,et al. Biopharmaceutical drug targeting to the brain , 2010, Journal of drug targeting.
[69] C. Peters,et al. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. , 2009, Biochemical and biophysical research communications.
[70] D. Geschwind,et al. Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer's disease , 2009, Nature Medicine.
[71] W. Pardridge. Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses. , 2008, Bioconjugate chemistry.
[72] I. Verma,et al. Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. , 2008, The American journal of pathology.
[73] W. Pardridge,et al. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood–brain barrier , 2007, Biotechnology and bioengineering.
[74] H. Gendelman,et al. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. , 2007, Progress in polymer science.
[75] Judy Lieberman,et al. Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.
[76] John J. Rossi,et al. Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.
[77] M. Manoharan,et al. RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.
[78] L. Mucke,et al. Antiamyloidogenic and Neuroprotective Functions of Cathepsin B: Implications for Alzheimer's Disease , 2006, Neuron.
[79] Inder M Verma,et al. Targeting BACE1 with siRNAs ameliorates Alzheimer disease neuropathology in a transgenic model , 2005, Nature Neuroscience.
[80] E. Stachowiak,et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[81] T. Nagai,et al. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: in vitro and in vivo studies. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[82] Steven G Potkin,et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.
[83] Inder M Verma,et al. Gene delivery of human apolipoprotein E alters brain Abeta burden in a mouse model of Alzheimer's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[84] D. Begley,et al. Brain Targeting Of Nerve Growth Factor Using Poly(Butylcyanoacrylate) Nanoparticles , 2004 .
[85] F. Gage,et al. Neprilysin Gene Transfer Reduces Human Amyloid Pathology in Transgenic Mice , 2003, The Journal of Neuroscience.
[86] Zhe-yu Chen,et al. Cationic liposome-mediated GDNF gene transfer after spinal cord injury. , 2002, Journal of neurotrauma.
[87] N. Muzyczka,et al. NGF gene transfer to intrinsic basal forebrain neurons increases cholinergic cell size and protects from age-related, spatial memory deficits in middle-aged rats , 2000, Brain Research.
[88] S. Tsuji,et al. Regional specificity of alterations in NGF, BDNF and NT‐3 levels in Alzheimer's disease , 1996, Neuroreport.
[89] U. Bickel,et al. Delivery of peptides and proteins through the blood-brain barrier. , 1993, Advanced drug delivery reviews.
[90] M. Eriksdotter,et al. A Review of Techniques for Biodelivery of Nerve Growth Factor (NGF) to the Brain in Relation to Alzheimer's Disease. , 2021, Advances in experimental medicine and biology.
[91] L. Dargahi,et al. Extracellular Vesicles as a Neprilysin Delivery System Memory Improvement in Alzheimer’s Disease , 2020, Iranian journal of pharmaceutical research : IJPR.
[92] A. Pliss,et al. Synergic treatment of Alzheimer’s disease with brain targeted nanoparticles incorporating NgR-siRNA and brain derived neurotrophic factor , 2020 .
[93] M. Sioud. RNA and CRISPR Interferences: Past, Present, and Future Perspectives. , 2020, Methods in molecular biology.
[94] Chi Zhang,et al. In vivo Evaluation and Alzheimer's Disease Treatment Outcome of siRNA Loaded Dual Targeting Drug Delivery System. , 2019, Current pharmaceutical biotechnology.
[95] P. Wong,et al. Intraventricular Delivery of siRNA Nanoparticles to the Central Nervous System. , 2015, Molecular therapy. Nucleic acids.
[96] A. Corrales,et al. Gene therapy strategies for Alzheimer disease , 2015 .
[97] S. Prakash,et al. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. , 2013, Biomaterials.
[98] R. Berry,et al. Beta-site amyloid precursor protein cleaving enzyme 1 levels become elevated in neurons around amyloid plaques: implications for Alzheimer's disease pathogenesis. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[99] W. Wurst,et al. RNA interference in mice. , 2007, Handbook of experimental pharmacology.
[100] J. Glorioso,et al. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. , 2006, Gene therapy.